Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...
Catalyst Pharmaceuticals Reports Strong Financial Results and Corporate Update
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently filed a Form 8-K with the Securities and Exchange Commission, detailing its financial performance for the third quarter of 2024. The company ...
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY IncreaseRecord Revenues Driven by Continued Organic Growth in its Rare ...
Zacks.com on MSN9d
Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2024, Catalyst Pharmaceutical (CPRX) reported revenue of $128.7 million, up 25.3% over the same period last year. EPS came in at $0.57, compared to -$0.24 in the ...
Business Insider9d
Catalyst Pharmaceuticals sees FY24 revenue $475M-$485M, consensus $473.67M
Revising full-year 2024 net product revenue guidance for FIRDAPSE to be between $300 million and $310 million; reaffirming FYCOMPA net product revenue guidance to be between $130 million and $135 ...